Kendall Capital Partners - aVenture Asset Manager Research
Kendall Capital Partners
Operating Status: Operating
Kendall Capital Partners: An early-stage venture capital firm.
Location
Boston, MA, US
Founded
2020
Kendall Capital Partners is an early-stage venture capital firm that primarily focuses on investing in innovative startups. The firm typically participates in Series A funding rounds, although it has been involved in other unspecified early-stage investments as well. Their investment strategy spans various sectors, with a notable emphasis on biotechnology and healthcare.
The firm boasts a diverse portfolio, including companies like Bilayer Therapeutics, Epi One, Eyenuk, Omnipulse Biosciences, and Rejuvenate Bio. Key partners at Kendall Capital Partners bring a wealth of experience from leading industry roles, enhancing their ability to provide strategic guidance and support. Their investment philosophy centers on fostering long-term growth and innovation, offering portfolio companies unique value-add services such as mentorship, industry connections, and operational expertise.
Kendall Capital Partners - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies5
Current Portfolio Count5
Top Investment Stages
Series A3 (60.0%)
Seed1 (20.0%)
Series B1 (20.0%)
Stage Mix
Series A 60%Seed 20%Series B 20%
Concentration shown as share of disclosed investments by stage.
